Lundbeck drug shows significantly improved functioning in major depressive disorder

According to Lundbeck, new trial results demonstrate that the firm's antidepressant Brintellix significantly improves overall functioning in people suffering from severe depression.
Lundbeck EVP for R&D Johan Luthman | Photo: PR / Lundbeck
Lundbeck EVP for R&D Johan Luthman | Photo: PR / Lundbeck

On Thursday morning, Lundbeck reported receiving positive data for the company's antidepressant Brintellix (generic name vortioxetin). In the firm's Relieve study, the drug has shown promise in improving severely depressed patients' ability to function.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading